Bristol/Gilead Joint Venture Targets 2005 Filing For HIV Fixed-Dose Combo

The joint venture is expected to use a new brand name for the fixed-dose combination of Sustiva and Truvada. Bristol and Gilead will receive sales revenues from the combination product “at percentages relative to the contribution represented by their individual products.”